Regencell Bioscience Holdings Limited
RGC
Rang in aandelen
#3381
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in... Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Aandeelprijs
$10.41
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$5.16B
Verandering (1 dag)
3.56%
Verandering (1 jaar)
-35.07%
Land
HK
Handel Regencell Bioscience Holdings Limited (RGC)
Categorie
Healthcare
P/B-ratio voor Regencell Bioscience Holdings Limited (RGC)
P/B-ratio op October 2026 TTM: 300.54
Volgens de meest recente financiële rapporten en aandelenkoers van Regencell Bioscience Holdings Limited is de huidige P/B-ratio (TTM) 300.54. Eind 2024 had het bedrijf een P/B-ratio van 5.08.
P/B-ratiohistoriek voor Regencell Bioscience Holdings Limited van 2019 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 300.54 | -82.66% |
| 2025 | 1.73K | 34,010.49% |
| 2024 | 5.08 | -79.61% |
| 2023 | 24.92 | -5.54% |
| 2022 | 26.38 | -179.45% |
| 2021 | -33.21 | -33.69% |
| 2020 | -50.08 | -30.65% |
| 2019 | -72.20 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -98.32% |
IN
|
